ClinicalTrials.gg
CompletedNCT06955104Updated Sep 3, 2025

Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients With Dyslipidemia

A Phase 3 interventional study of JW0108 + C2407 and JW0108 + C2407 placebo in Dyslipidemia, sponsored by JW Pharmaceutical. Completed at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-09-03.

Sponsored by JW Pharmaceutical · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
145
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 155 studies in Dyslipidemias with a site in Korea, Republic of — 30 open to participants now, 39 under way, 5 of them phase 3. Dyslipidemias · Korea, Republic of.

Enrollment
44th of 124
145 · median 80
Started
2025
with 13 others
Phase 3
31 of 155
3 open now
Registered
133rd of 155
by date
Lead sponsor
6 of 155
JW Pharmaceutical

Among the 155 studies in Dyslipidemias with a site in Korea, Republic of, this one is the 44th largest by enrollment of the 124 interventional ones that give a count, is one of 14 that started in 2025, is one of 31 in phase 3, and was the 133rd registered.

Dyslipidemias

1,250 studies on the registry are indexed under Dyslipidemias; 178 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

30 of the 155 studies in Dyslipidemias with a site in Korea, Republic of are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies in Dyslipidemias with a site in Korea, Republic of, or all of them as a file.
02

Study summary

A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients with Dyslipidemia

Read the detailed description

To evaluate the efficacy and safety of JW0108+C2407 in dyslipidemia patients

03

Conditions studied

  • Dyslipidemia

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age of 19 years old at the time of written
  • Patients with dyslipidemia

Exclusion criteria

Exclusion Criteria:

  • Secondary dyslipidemia
  • Patient who does not meet the specified TG, LDL-C level
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
145 participants (actual)

Study arms

  • Experimental
    Experimental Group: JW0108 + C2407

    For 8weeks QD(Quaque Die)

    Drug: JW0108 + C2407

  • Active comparator
    Control Group: JW0108 + C2407 placebo

    For 8weeks QD(Quaque Die)

    Drug: JW0108 + C2407 placebo

Interventions

  • DrugJW0108 + C2407

    JW0108 + C2407

  • DrugJW0108 + C2407 placebo

    JW0108 + C2407 placebo

06

What researchers measure

Primary outcomes

  1. Percent change from baseline in LDL-C

    Check LDL-C

    Time frame: Week 8

Secondary outcomes

  1. Efficacy and Safety: Change from baseline in LDL-C (mg/dL)

    Check LDL-C

    Time frame: Week 8

07

Study locations

1 site
  • Asan Medical Center
    Seoul, 05505, South Korea
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Jul 2025, 3 months.

Of 52 industry-sponsored phase 3 interventional studies under Dyslipidemias, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's 3 months is below that.

Counting every sponsor, half of 62 studies reached it within 22 months; a quarter within 12 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2025
First posted
May 2, 2025
StartActual
Apr 3, 2025
Primary completionActual
Jul 30, 2025
CompletionActual
Jul 30, 2025
Last update
Sep 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06955104
Lead sponsor
JW Pharmaceutical
Responsible party
Sponsor
First posted
May 2, 2025
Start date
Apr 3, 2025
Primary completion
Jul 30, 2025
Completion
Jul 30, 2025
Last update
Sep 3, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion